Statin therapy in critical illness: an international survey of intensive care physicians’ opinions, attitudes and practice View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-06-28

AUTHORS

Manu Shankar-Hari, Peter S Kruger, Stefania Di Gangi, Damon C Scales, Gavin D Perkins, Danny F McAuley, Marius Terblanche

ABSTRACT

BackgroundPleotropic effects of statins on inflammation are hypothesised to attenuate the severity of and possibly prevent the occurrence of the host inflammatory response to pathogen and infection-related acute organ failure. We conducted an international survey of intensive care physicians in Australia, New Zealand (ANZ) and United Kingdom (UK). The aims of the survey were to assess the current prescribing practice patterns, attitudes towards prescribing statin therapy in critically ill patients and opinions on the need for an interventional trial of statin therapy in critically ill patients.MethodsSurvey questions were developed through an iterative process. An expert group reviewed the resulting 26 items for face and content validity and clarity. The questions were further refined following pilot testing by ICU physicians from Australia, Canada and the UK. We used the online Smart SurveyTM software to administer the survey.ResultsOf 239 respondents (62 from ANZ and 177 from UK) 58% worked in teaching hospitals; most (78.2%) practised in ‘closed’ units with a mixed medical and surgical case mix (71.0%). The most frequently prescribed statins were simvastatin (77.6%) in the UK and atorvastatin (66.1%) in ANZ. The main reasons cited to explain the choice of statin were preadmission prescription and pharmacy availability. Most respondents reported never starting statins to prevent (65.3%) or treat (89.1%) organ dysfunction. Only a minority (10%) disagreed with a statement that the risks of major side effects of statins when prescribed in critically ill patients were low. The majority (84.5%) of respondents strongly agreed that a clinical trial of statins for prevention is needed. More than half (56.5%) favoured rates of organ failure as the primary outcome for such a trial, while a minority (40.6%) favoured mortality.ConclusionsDespite differences in type of statins prescribed, critical care physicians in the UK and ANZ reported similar prescription practices. Respondents from both communities agreed that a trial is needed to test whether statins can prevent the onset of new organ failure in patients with sepsis. More... »

PAGES

13

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1472-6904-12-13

DOI

http://dx.doi.org/10.1186/1472-6904-12-13

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051450900

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22742644


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Australia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Critical Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Critical Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Collection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Prescriptions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Knowledge, Attitudes, Practice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "New Zealand", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pharmacy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Physicians", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Patterns, Physicians'", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.420545.2", 
          "name": [
            "Division of Asthma, Allergy and Lung Biology, King\u2019s College London, London, UK", 
            "Critical Care and Anesthesia Research Group, King\u2019s Health Partners Academic Health Sciences Centre, London, UK", 
            "Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shankar-Hari", 
        "givenName": "Manu", 
        "id": "sg:person.01242172705.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242172705.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Queensland, Brisbane, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1003.2", 
          "name": [
            "Princess Alexandra Hospital, Wooloongabba, Brisbane, Australia", 
            "University of Queensland, Brisbane, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kruger", 
        "givenName": "Peter S", 
        "id": "sg:person.01336432744.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336432744.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.420545.2", 
          "name": [
            "Division of Asthma, Allergy and Lung Biology, King\u2019s College London, London, UK", 
            "Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Gangi", 
        "givenName": "Stefania", 
        "id": "sg:person.010706045534.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010706045534.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada", 
          "id": "http://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Interdepartmental Division of Critical Care, University of Toronto, Toronto, Canada", 
            "Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scales", 
        "givenName": "Damon C", 
        "id": "sg:person.01110343356.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110343356.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Warwick Clinical Trials Unit, Warwick Medical, University of Warwick School, Warwick, UK", 
          "id": "http://www.grid.ac/institutes/grid.7372.1", 
          "name": [
            "Warwick Clinical Trials Unit, Warwick Medical, University of Warwick School, Warwick, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perkins", 
        "givenName": "Gavin D", 
        "id": "sg:person.01243160227.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243160227.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre for Infection and Immunity, The Queen\u2019s University of Belfast, Belfast, UK", 
          "id": "http://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "Centre for Infection and Immunity, The Queen\u2019s University of Belfast, Belfast, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McAuley", 
        "givenName": "Danny F", 
        "id": "sg:person.016040610317.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016040610317.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.420545.2", 
          "name": [
            "Division of Asthma, Allergy and Lung Biology, King\u2019s College London, London, UK", 
            "Critical Care and Anesthesia Research Group, King\u2019s Health Partners Academic Health Sciences Centre, London, UK", 
            "Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Terblanche", 
        "givenName": "Marius", 
        "id": "sg:person.01015357005.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015357005.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1476-0711-11-13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040573060", 
          "https://doi.org/10.1186/1476-0711-11-13"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200422120-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009292170", 
          "https://doi.org/10.2165/00019053-200422120-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc4854", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017687667", 
          "https://doi.org/10.1186/cc4854"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc5056", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024736165", 
          "https://doi.org/10.1186/cc5056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc2917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035152195", 
          "https://doi.org/10.1186/cc2917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc10086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029421295", 
          "https://doi.org/10.1186/cc10086"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc10063", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052144400", 
          "https://doi.org/10.1186/cc10063"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06-28", 
    "datePublishedReg": "2012-06-28", 
    "description": "BackgroundPleotropic effects of statins on inflammation are hypothesised to attenuate the severity of and possibly prevent the occurrence of the host inflammatory response to pathogen and infection-related acute organ failure. We conducted an international survey of intensive care physicians in Australia, New Zealand (ANZ) and United Kingdom (UK). The aims of the survey were to assess the current prescribing practice patterns, attitudes towards prescribing statin therapy in critically ill patients and opinions on the need for an interventional trial of statin therapy in critically ill patients.MethodsSurvey questions were developed through an iterative process. An expert group reviewed the resulting 26 items for face and content validity and clarity. The questions were further refined following pilot testing by ICU physicians from Australia, Canada and the UK. We used the online Smart SurveyTM software to administer the survey.ResultsOf 239 respondents (62 from ANZ and 177 from UK) 58% worked in teaching hospitals; most (78.2%) practised in \u2018closed\u2019 units with a mixed medical and surgical case mix (71.0%). The most frequently prescribed statins were simvastatin (77.6%) in the UK and atorvastatin (66.1%) in ANZ. The main reasons cited to explain the choice of statin were preadmission prescription and pharmacy availability. Most respondents reported never starting statins to prevent (65.3%) or treat (89.1%) organ dysfunction. Only a minority (10%) disagreed with a statement that the risks of major side effects of statins when prescribed in critically ill patients were low. The majority (84.5%) of respondents strongly agreed that a clinical trial of statins for prevention is needed. More than half (56.5%) favoured rates of organ failure as the primary outcome for such a trial, while a minority (40.6%) favoured mortality.ConclusionsDespite differences in type of statins prescribed, critical care physicians in the UK and ANZ reported similar prescription practices. Respondents from both communities agreed that a trial is needed to test whether statins can prevent the onset of new organ failure in patients with sepsis.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1472-6904-12-13", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2784459", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1028423", 
        "issn": [
          "1472-6904"
        ], 
        "name": "BMC Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "intensive care physicians", 
      "statin therapy", 
      "organ failure", 
      "ill patients", 
      "care physicians", 
      "choice of statin", 
      "new organ failure", 
      "acute organ failure", 
      "type of statin", 
      "major side effects", 
      "critical care physicians", 
      "host inflammatory response", 
      "surgical case mix", 
      "pharmacy availability", 
      "interventional trials", 
      "organ dysfunction", 
      "primary outcome", 
      "critical illness", 
      "ICU physicians", 
      "prescription practices", 
      "clinical trials", 
      "inflammatory response", 
      "practice patterns", 
      "teaching hospital", 
      "statins", 
      "side effects", 
      "case mix", 
      "patients", 
      "majority of respondents", 
      "physicians", 
      "therapy", 
      "international survey", 
      "ConclusionsDespite differences", 
      "trials", 
      "content validity", 
      "Most respondents", 
      "United Kingdom", 
      "pilot testing", 
      "failure", 
      "ANZ", 
      "sepsis", 
      "inflammation", 
      "dysfunction", 
      "hospital", 
      "atorvastatin", 
      "expert group", 
      "illness", 
      "simvastatin", 
      "mortality", 
      "respondents", 
      "severity", 
      "prevention", 
      "outcomes", 
      "prescription", 
      "minority", 
      "risk", 
      "survey", 
      "onset", 
      "effect", 
      "pathogens", 
      "group", 
      "aim", 
      "majority", 
      "practice", 
      "main reason", 
      "response", 
      "half", 
      "differences", 
      "testing", 
      "attitudes", 
      "occurrence", 
      "rate", 
      "opinion", 
      "New Zealand", 
      "Australia", 
      "need", 
      "items", 
      "patterns", 
      "questions", 
      "reasons", 
      "units", 
      "types", 
      "Canada", 
      "validity", 
      "choice", 
      "Kingdom", 
      "face", 
      "availability", 
      "statements", 
      "clarity", 
      "iterative process", 
      "Zealand", 
      "community", 
      "mix", 
      "software", 
      "process"
    ], 
    "name": "Statin therapy in critical illness: an international survey of intensive care physicians\u2019 opinions, attitudes and practice", 
    "pagination": "13", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051450900"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1472-6904-12-13"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22742644"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1472-6904-12-13", 
      "https://app.dimensions.ai/details/publication/pub.1051450900"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_582.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1472-6904-12-13"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1472-6904-12-13'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1472-6904-12-13'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1472-6904-12-13'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1472-6904-12-13'


 

This table displays all metadata directly associated to this object as RDF triples.

300 TRIPLES      21 PREDICATES      142 URIs      127 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1472-6904-12-13 schema:about N0d6e871900a848629a34294721a25e95
2 N17461ac3b32f46b69c74d1d94a6518a8
3 N1cc51e11983848c5a423a25f34b25552
4 N20b4ca9452da4095be5f0d0a6a674402
5 N2564dd295c3d40ab899a9709eb6f1d23
6 N2fea82e1020c4e31b2e4dcc0ccf0081e
7 N3bebd7851a78445d9c9f9a97013a2c5c
8 N416cfce9796b49609440c4eba1b2907c
9 N7ae25f492a1841829258e27a8e2a0f60
10 Naf5f96c610f2469da79437683492a421
11 Nce01dd5b5706443798dc2cfa725a7a4e
12 Nd3799359b0ec4f53b5f4fa63ae89c0d4
13 Nd6d6a2a0d0ad429689451d6f0fe19af3
14 Nfcaeee43d61846df926238b82d234af4
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N90b730d748784353aaf5602fe29e7ed5
18 schema:citation sg:pub.10.1186/1476-0711-11-13
19 sg:pub.10.1186/cc10063
20 sg:pub.10.1186/cc10086
21 sg:pub.10.1186/cc2917
22 sg:pub.10.1186/cc4854
23 sg:pub.10.1186/cc5056
24 sg:pub.10.2165/00019053-200422120-00003
25 schema:datePublished 2012-06-28
26 schema:datePublishedReg 2012-06-28
27 schema:description BackgroundPleotropic effects of statins on inflammation are hypothesised to attenuate the severity of and possibly prevent the occurrence of the host inflammatory response to pathogen and infection-related acute organ failure. We conducted an international survey of intensive care physicians in Australia, New Zealand (ANZ) and United Kingdom (UK). The aims of the survey were to assess the current prescribing practice patterns, attitudes towards prescribing statin therapy in critically ill patients and opinions on the need for an interventional trial of statin therapy in critically ill patients.MethodsSurvey questions were developed through an iterative process. An expert group reviewed the resulting 26 items for face and content validity and clarity. The questions were further refined following pilot testing by ICU physicians from Australia, Canada and the UK. We used the online Smart SurveyTM software to administer the survey.ResultsOf 239 respondents (62 from ANZ and 177 from UK) 58% worked in teaching hospitals; most (78.2%) practised in ‘closed’ units with a mixed medical and surgical case mix (71.0%). The most frequently prescribed statins were simvastatin (77.6%) in the UK and atorvastatin (66.1%) in ANZ. The main reasons cited to explain the choice of statin were preadmission prescription and pharmacy availability. Most respondents reported never starting statins to prevent (65.3%) or treat (89.1%) organ dysfunction. Only a minority (10%) disagreed with a statement that the risks of major side effects of statins when prescribed in critically ill patients were low. The majority (84.5%) of respondents strongly agreed that a clinical trial of statins for prevention is needed. More than half (56.5%) favoured rates of organ failure as the primary outcome for such a trial, while a minority (40.6%) favoured mortality.ConclusionsDespite differences in type of statins prescribed, critical care physicians in the UK and ANZ reported similar prescription practices. Respondents from both communities agreed that a trial is needed to test whether statins can prevent the onset of new organ failure in patients with sepsis.
28 schema:genre article
29 schema:isAccessibleForFree true
30 schema:isPartOf N79551f4422994485ba0cb5210739ef89
31 Nc6e438fcd4744f10a3aff8a301a92f64
32 sg:journal.1028423
33 schema:keywords ANZ
34 Australia
35 Canada
36 ConclusionsDespite differences
37 ICU physicians
38 Kingdom
39 Most respondents
40 New Zealand
41 United Kingdom
42 Zealand
43 acute organ failure
44 aim
45 atorvastatin
46 attitudes
47 availability
48 care physicians
49 case mix
50 choice
51 choice of statin
52 clarity
53 clinical trials
54 community
55 content validity
56 critical care physicians
57 critical illness
58 differences
59 dysfunction
60 effect
61 expert group
62 face
63 failure
64 group
65 half
66 hospital
67 host inflammatory response
68 ill patients
69 illness
70 inflammation
71 inflammatory response
72 intensive care physicians
73 international survey
74 interventional trials
75 items
76 iterative process
77 main reason
78 major side effects
79 majority
80 majority of respondents
81 minority
82 mix
83 mortality
84 need
85 new organ failure
86 occurrence
87 onset
88 opinion
89 organ dysfunction
90 organ failure
91 outcomes
92 pathogens
93 patients
94 patterns
95 pharmacy availability
96 physicians
97 pilot testing
98 practice
99 practice patterns
100 prescription
101 prescription practices
102 prevention
103 primary outcome
104 process
105 questions
106 rate
107 reasons
108 respondents
109 response
110 risk
111 sepsis
112 severity
113 side effects
114 simvastatin
115 software
116 statements
117 statin therapy
118 statins
119 surgical case mix
120 survey
121 teaching hospital
122 testing
123 therapy
124 trials
125 type of statin
126 types
127 units
128 validity
129 schema:name Statin therapy in critical illness: an international survey of intensive care physicians’ opinions, attitudes and practice
130 schema:pagination 13
131 schema:productId N2394832c436b48a39140ea53a6536687
132 N5f18b60a15fd488ca7c3880642f495ae
133 N775ed9f0d1944a108981ff3854cc9ad9
134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051450900
135 https://doi.org/10.1186/1472-6904-12-13
136 schema:sdDatePublished 2022-10-01T06:38
137 schema:sdLicense https://scigraph.springernature.com/explorer/license/
138 schema:sdPublisher N937c002fd7494db19b2d19696148d854
139 schema:url https://doi.org/10.1186/1472-6904-12-13
140 sgo:license sg:explorer/license/
141 sgo:sdDataset articles
142 rdf:type schema:ScholarlyArticle
143 N0cc10703ce894dddb0024171c46acf93 rdf:first sg:person.010706045534.01
144 rdf:rest N9cf2b8ad35f045028249542c7171ac20
145 N0d6e871900a848629a34294721a25e95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name United Kingdom
147 rdf:type schema:DefinedTerm
148 N17461ac3b32f46b69c74d1d94a6518a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Australia
150 rdf:type schema:DefinedTerm
151 N1cc51e11983848c5a423a25f34b25552 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Data Collection
153 rdf:type schema:DefinedTerm
154 N20b4ca9452da4095be5f0d0a6a674402 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Drug Prescriptions
156 rdf:type schema:DefinedTerm
157 N2394832c436b48a39140ea53a6536687 schema:name doi
158 schema:value 10.1186/1472-6904-12-13
159 rdf:type schema:PropertyValue
160 N2564dd295c3d40ab899a9709eb6f1d23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name New Zealand
162 rdf:type schema:DefinedTerm
163 N2f4aed1bf05f4ea288d3906345daa0b9 rdf:first sg:person.016040610317.75
164 rdf:rest N9c3fa5d48a68452c8fa8969d541a4843
165 N2fea82e1020c4e31b2e4dcc0ccf0081e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
167 rdf:type schema:DefinedTerm
168 N3bebd7851a78445d9c9f9a97013a2c5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Critical Care
170 rdf:type schema:DefinedTerm
171 N416cfce9796b49609440c4eba1b2907c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Pilot Projects
173 rdf:type schema:DefinedTerm
174 N4cdfe4ecc0824e5f8e32b32335c1912d rdf:first sg:person.01336432744.38
175 rdf:rest N0cc10703ce894dddb0024171c46acf93
176 N5f18b60a15fd488ca7c3880642f495ae schema:name dimensions_id
177 schema:value pub.1051450900
178 rdf:type schema:PropertyValue
179 N775ed9f0d1944a108981ff3854cc9ad9 schema:name pubmed_id
180 schema:value 22742644
181 rdf:type schema:PropertyValue
182 N79551f4422994485ba0cb5210739ef89 schema:issueNumber 1
183 rdf:type schema:PublicationIssue
184 N7ae25f492a1841829258e27a8e2a0f60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Pharmacy
186 rdf:type schema:DefinedTerm
187 N8452a06a7ba44331926e9aa7afc0a85a rdf:first sg:person.01243160227.13
188 rdf:rest N2f4aed1bf05f4ea288d3906345daa0b9
189 N90b730d748784353aaf5602fe29e7ed5 rdf:first sg:person.01242172705.25
190 rdf:rest N4cdfe4ecc0824e5f8e32b32335c1912d
191 N937c002fd7494db19b2d19696148d854 schema:name Springer Nature - SN SciGraph project
192 rdf:type schema:Organization
193 N9c3fa5d48a68452c8fa8969d541a4843 rdf:first sg:person.01015357005.25
194 rdf:rest rdf:nil
195 N9cf2b8ad35f045028249542c7171ac20 rdf:first sg:person.01110343356.39
196 rdf:rest N8452a06a7ba44331926e9aa7afc0a85a
197 Naf5f96c610f2469da79437683492a421 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Health Knowledge, Attitudes, Practice
199 rdf:type schema:DefinedTerm
200 Nc6e438fcd4744f10a3aff8a301a92f64 schema:volumeNumber 12
201 rdf:type schema:PublicationVolume
202 Nce01dd5b5706443798dc2cfa725a7a4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Critical Illness
204 rdf:type schema:DefinedTerm
205 Nd3799359b0ec4f53b5f4fa63ae89c0d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Physicians
207 rdf:type schema:DefinedTerm
208 Nd6d6a2a0d0ad429689451d6f0fe19af3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Practice Patterns, Physicians'
210 rdf:type schema:DefinedTerm
211 Nfcaeee43d61846df926238b82d234af4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Humans
213 rdf:type schema:DefinedTerm
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
218 schema:name Clinical Sciences
219 rdf:type schema:DefinedTerm
220 sg:grant.2784459 http://pending.schema.org/fundedItem sg:pub.10.1186/1472-6904-12-13
221 rdf:type schema:MonetaryGrant
222 sg:journal.1028423 schema:issn 1472-6904
223 schema:name BMC Clinical Pharmacology
224 schema:publisher Springer Nature
225 rdf:type schema:Periodical
226 sg:person.01015357005.25 schema:affiliation grid-institutes:grid.420545.2
227 schema:familyName Terblanche
228 schema:givenName Marius
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015357005.25
230 rdf:type schema:Person
231 sg:person.010706045534.01 schema:affiliation grid-institutes:grid.420545.2
232 schema:familyName Di Gangi
233 schema:givenName Stefania
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010706045534.01
235 rdf:type schema:Person
236 sg:person.01110343356.39 schema:affiliation grid-institutes:grid.413104.3
237 schema:familyName Scales
238 schema:givenName Damon C
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110343356.39
240 rdf:type schema:Person
241 sg:person.01242172705.25 schema:affiliation grid-institutes:grid.420545.2
242 schema:familyName Shankar-Hari
243 schema:givenName Manu
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242172705.25
245 rdf:type schema:Person
246 sg:person.01243160227.13 schema:affiliation grid-institutes:grid.7372.1
247 schema:familyName Perkins
248 schema:givenName Gavin D
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243160227.13
250 rdf:type schema:Person
251 sg:person.01336432744.38 schema:affiliation grid-institutes:grid.1003.2
252 schema:familyName Kruger
253 schema:givenName Peter S
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336432744.38
255 rdf:type schema:Person
256 sg:person.016040610317.75 schema:affiliation grid-institutes:grid.4777.3
257 schema:familyName McAuley
258 schema:givenName Danny F
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016040610317.75
260 rdf:type schema:Person
261 sg:pub.10.1186/1476-0711-11-13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040573060
262 https://doi.org/10.1186/1476-0711-11-13
263 rdf:type schema:CreativeWork
264 sg:pub.10.1186/cc10063 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052144400
265 https://doi.org/10.1186/cc10063
266 rdf:type schema:CreativeWork
267 sg:pub.10.1186/cc10086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029421295
268 https://doi.org/10.1186/cc10086
269 rdf:type schema:CreativeWork
270 sg:pub.10.1186/cc2917 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035152195
271 https://doi.org/10.1186/cc2917
272 rdf:type schema:CreativeWork
273 sg:pub.10.1186/cc4854 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017687667
274 https://doi.org/10.1186/cc4854
275 rdf:type schema:CreativeWork
276 sg:pub.10.1186/cc5056 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024736165
277 https://doi.org/10.1186/cc5056
278 rdf:type schema:CreativeWork
279 sg:pub.10.2165/00019053-200422120-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009292170
280 https://doi.org/10.2165/00019053-200422120-00003
281 rdf:type schema:CreativeWork
282 grid-institutes:grid.1003.2 schema:alternateName University of Queensland, Brisbane, Australia
283 schema:name Princess Alexandra Hospital, Wooloongabba, Brisbane, Australia
284 University of Queensland, Brisbane, Australia
285 rdf:type schema:Organization
286 grid-institutes:grid.413104.3 schema:alternateName Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
287 schema:name Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
288 Interdepartmental Division of Critical Care, University of Toronto, Toronto, Canada
289 rdf:type schema:Organization
290 grid-institutes:grid.420545.2 schema:alternateName Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK
291 schema:name Critical Care and Anesthesia Research Group, King’s Health Partners Academic Health Sciences Centre, London, UK
292 Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK
293 Division of Asthma, Allergy and Lung Biology, King’s College London, London, UK
294 rdf:type schema:Organization
295 grid-institutes:grid.4777.3 schema:alternateName Centre for Infection and Immunity, The Queen’s University of Belfast, Belfast, UK
296 schema:name Centre for Infection and Immunity, The Queen’s University of Belfast, Belfast, UK
297 rdf:type schema:Organization
298 grid-institutes:grid.7372.1 schema:alternateName Warwick Clinical Trials Unit, Warwick Medical, University of Warwick School, Warwick, UK
299 schema:name Warwick Clinical Trials Unit, Warwick Medical, University of Warwick School, Warwick, UK
300 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...